Amantadine hydrochloride in the treatment of parkinsonism: A placebo-controlled double-blind study

This report covers a review of the literature and a description of a double-blind placebo-controlled trial, of 200 mg of amantadine hydrochloride daily in the treatment of 23 parkinsonian patients. Statistical analysis of clinical results showed a significant improvement in rigidity and tremor at rest and a fair improvement in initiating movements and alertness. Subjective mood elevation was not confirmed by statistical analysis. Gait, voice control, jaw tremor and salivation showed no statistical improvement, while eye convergence may be adversely affected. Side-effects were minimal. Amantadine hydrochloride (Symmetrel, Geigy) appears to have real value in the treatment of parkinsonism.